PDL1 immunohistochemistry in canine neoplasms: Validation of commercial antibodies, standardization of evaluation, and scoring systems
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PDL1 immunohistochemistry in canine neoplasms: Validation of commercial antibodies, standardization of evaluation, and scoring systems
Authors
Keywords
-
Journal
VETERINARY PATHOLOGY
Volume -, Issue -, Pages -
Publisher
SAGE Publications
Online
2023-11-03
DOI
10.1177/03009858231209410
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Atlas of PD-L1 for Pathologists: Indications, Scores, Diagnostic Platforms and Reporting Systems
- (2022) Stefano Marletta et al. Journal of Personalized Medicine
- Comparative Evaluation of Tumor-Infiltrating Lymphocytes in Companion Animals: Immuno-Oncology as a Relevant Translational Model for Cancer Therapy
- (2022) Christopher J. Pinard et al. Cancers
- Prognostic value of tumor-infiltrating immune cells and immune checkpoints in elderly head-and-neck squamous cell carcinoma patients undergoing definitive (chemo)radiotherapy
- (2022) Alexander Rühle et al. Radiation Oncology
- Development of Monoclonal Antibodies Targeting Canine PD-L1 and PD-1 and Their Clinical Relevance in Canine Apocrine Gland Anal Sac Adenocarcinoma
- (2022) Lucia Minoli et al. Cancers
- High expression of ACE2 and TMPRSS2 and clinical characteristics of COVID-19 in colorectal cancer patients
- (2021) Chao Liu et al. npj Precision Oncology
- PD-L1 as a biomarker of response to immune-checkpoint inhibitors
- (2021) Deborah Blythe Doroshow et al. Nature Reviews Clinical Oncology
- Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs
- (2021) Stanislav Pantelyushin et al. Cancers
- Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC
- (2021) Mengke Niu et al. Experimental Hematology & Oncology
- Modeling human tumor-immune environments in vivo for the preclinical assessment of immunotherapies
- (2021) Bethany Bareham et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade
- (2021) Sneha Berry et al. SCIENCE
- PD−L1 immunostaining: what pathologists need to know
- (2021) Mohammed Akhtar et al. Diagnostic Pathology
- Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines
- (2021) Christopher J. Pinard et al. VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY
- Therapy for Stage IV Non–Small-Cell Lung Cancer Without Driver Alterations: ASCO and OH (CCO) Joint Guideline Update
- (2020) Nasser H. Hanna et al. JOURNAL OF CLINICAL ONCOLOGY
- Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function
- (2020) Jin Wook Choi et al. PLoS One
- Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
- (2020) Qingyang Lei et al. Frontiers in Cell and Developmental Biology
- Nuclear localization of PD-L1: artifact or reality?
- (2019) Hara Polioudaki et al. CELLULAR ONCOLOGY
- Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases
- (2019) Dennis P. O’Malley et al. MODERN PATHOLOGY
- Role of PD-L1 Expression in Non-Small Cell Lung Cancer and Their Prognostic Significance according to Clinicopathological Factors and Diagnostic Markers
- (2019) Konrad Pawelczyk et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms
- (2018) Christina Koppel et al. MODERN PATHOLOGY
- PD-L1
- (2017) Anthousa Kythreotou et al. JOURNAL OF CLINICAL PATHOLOGY
- Defining the optimal murine models to investigate immune checkpoint blockers and their combination with other immunotherapies
- (2016) M. F. Sanmamed et al. ANNALS OF ONCOLOGY
- PD-L1 Expression in Human Placentas and Gestational Trophoblastic Diseases
- (2016) Emanuela Veras et al. INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY
- PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis
- (2016) Nathaniel A. Slater et al. JOURNAL OF CUTANEOUS PATHOLOGY
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- PD-L1 expression in human cancers and its association with clinical outcomes
- (2016) Jinming Yu et al. OncoTargets and Therapy
- PD-L1 expression in non-small cell lung cancer: Correlations with genetic alterations
- (2016) Andreas H. Scheel et al. OncoImmunology
- Immunohistochemical Analysis of PD-L1 Expression in Canine Malignant Cancers and PD-1 Expression on Lymphocytes in Canine Oral Melanoma
- (2016) Naoya Maekawa et al. PLoS One
- Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial
- (2015) Jeffrey S Weber et al. LANCET ONCOLOGY
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- PD-1 and Its Ligands in Tolerance and Immunity
- (2008) Mary E. Keir et al. Annual Review of Immunology
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started